Opin vísindi

Changes in invasive pneumococcal disease caused by streptococcus pneumoniae serotype 1 following introduction of pcv10 and pcv13 : Findings from the pserenade project

Changes in invasive pneumococcal disease caused by streptococcus pneumoniae serotype 1 following introduction of pcv10 and pcv13 : Findings from the pserenade project


Title: Changes in invasive pneumococcal disease caused by streptococcus pneumoniae serotype 1 following introduction of pcv10 and pcv13 : Findings from the pserenade project
Author: PSERENADE Team
Date: 2021-03-27
Language: English
Scope:
University/Institute: Landspitali - The National University Hospital of Iceland
Department: Faculty of Medicine
Clinical Laboratory Services, Diagnostics and Blood Bank
Series: Microorganisms; 9(4)
ISSN: 2076-2607
DOI: https://doi.org/10.3390/microorganisms9040696
Subject: Pneumókokkar; Bólusetningar; Invasive pneumococcal disease; Pneumococcal conjugate vaccines; Serotypes; Vaccine impact; Microbiology; Microbiology (medical); Virology
URI: https://hdl.handle.net/20.500.11815/3204

Show full item record

Citation:

PSERENADE Team 2021 , ' Changes in invasive pneumococcal disease caused by streptococcus pneumoniae serotype 1 following introduction of pcv10 and pcv13 : Findings from the pserenade project ' , Microorganisms , vol. 9 , no. 4 , 696 . https://doi.org/10.3390/microorganisms9040696

Abstract:

Streptococcus pneumoniae serotype 1 (ST1) was an important cause of invasive pneumococ-cal disease (IPD) globally before the introduction of pneumococcal conjugate vaccines (PCVs) con-taining ST1 antigen. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERE‐ NADE) project gathered ST1 IPD surveillance data from sites globally and aimed to estimate PCV10/13 impact on ST1 IPD incidence. We estimated ST1 IPD incidence rate ratios (IRRs) compar-ing the pre‐PCV10/13 period to each post‐PCV10/13 year by site using a Bayesian multi‐level, mixed-effects Poisson regression and all‐site IRRs using a linear mixed‐effects regression (N = 45 sites). Following PCV10/13 introduction, the incidence rate (IR) of ST1 IPD declined among all ages. After six years of PCV10/13 use, the all‐site IRR was 0.05 (95% credibility interval 0.04–0.06) for all ages, 0.05 (0.04–0.05) for <5 years of age, 0.08 (0.06–0.09) for 5–17 years, 0.06 (0.05–0.08) for 18–49 years, 0.06 (0.05–0.07) for 50–64 years, and 0.05 (0.04–0.06) for ≥65 years. PCV10/13 use in infant immunization programs was followed by a 95% reduction in ST1 IPD in all ages after approximately 6 years. Limited data availability from the highest ST1 disease burden countries using a 3+0 schedule constrains generalizability and data from these settings are needed.

Description:

Funding text 1 Funding: The PSERENADE project is funded by the Bill and Melinda Gates Foundation as part of the World Health Organization Pneumococcal Vaccines Technical Coordination Project, grant num‐ ber INV‐010429/OPP1189065. Funding text 2 Conflicts of Interest: KH conducted the study and analyses while working at the Johns Hopkins School of Public Health but is an employee at Pfizer, Inc. as of 26 October 2020. MDK reports grants from Merck, personal fees from Merck, and grants from Pfizer, outside the submitted work. JCB reports funding from Pfizer in the past year, unrelated to the submitted work. JAS reports grants from the Bill & Melinda Gates Foundation, the Wellcome Trust, the UK MRC, National Institute of Health Research, outside the submitted work. MCB reports lectures fee from MSD outside from submitted work. AS reports grants and personal fees from Pfizer and personal fees from MSD and Sanofi Pasteur, outside the submitted work. ML has been a member of advisory boards and has received speakers honoraria from Pfizer and Merck. German pneumococcal surveillance has been supported by Pfizer and Merck. SD reports grant from Pfizer, outside the submitted work. KA re‐ ports a grant from Merck, outside the submitted work. AvG as received researching funding from Pfizer (last year 2017, Pfizer Investigator‐Initiated Research [IIR] Program IIR WI 194379); attended advisory board meetings for Pfizer and Merck. CMA reports grants and personal fees from Pfizer, Qiagen and BioMerieux and grants from Genomica SAU, outside the submitted work. AM‐research support to my institution from Pfizer and Merck; honoraria for advisory board membership from GlaxoSmithKline, Merck and Pfizer. SNL performs contract research for GSK, Pfizer, Sanofi Pasteur on behalf of St. George’s University of London, but receives no personal remuneration. IY stated she was a member of mRNA‐1273 study group and has received funding to her institution to conduct clinical research from BioFire, MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Novavax, Sanofi‐Pasteur, and Micron. RD has received grants/research support from Pfizer, Merck Sharp & Dohme and Medimmune; has been a scientific consultant for Pfizer, MeMed, Merck Sharp & Dohme, and Biondvax; had served on advisory boards of Pfizer, Merck Sharp & Dohme and Biondvax and has been a speaker for Pfizer. LLH reports research grants to her institution from GSK, Pfizer and Merck. JDK has received an unrestricted grant‐in‐aid from Pfizer Canada that sup‐ ports, in part, the CASPER invasive pneumococcal disease surveillance project. MH received an educational grant from Pfizer AG for partial support of this project. However, Pfizer AG had no role in the data analysis and content of the manuscript. MC has previously received a professional fee from Pfizer (Ireland), an unrestricted research grant from Pfizer Ireland (2007–2016) and an In‐ vestigator Initiated Reward from Pfizer Ireland in 2018 (W1243730). CLB, MD has intellectual prop‐ erty in BioFire Diagnostics and receives royalties through the University of Utah. CLB is an advisor to IDbyDNA. AK reports personal fees from Pfizer, outside the submitted work. MT reports grants from GlaxoSmithKline and grants from Pfizer Inc. to the Finnish Institute for Health and Welfare for research projects outside the submitted work, in which she has been a co‐investigator. JCS re‐ ports had received assistance from Pfizer for attending to scientific meetings outside the submitted work. SCGA received travel grant from Pfizer. BL had two research grants from Pfizer on Strepto‐ coccus pneumoniae. EV reports grants from French public health agency, during the conduct of the study; grants from Pfizer, grants from Merck, outside the submitted work. NBZ has received inves‐ tigator‐initiated research grants from GlaxoSmithKline, Takeda Pharmaceuticals, Merck and the Se‐ rum Institute of India, all unrelated to this research. CGS reports grant funding from Pfizer, Merck, and AstraZeneca in the past 3 years. NMvS reports grants and fee for service from Pfizer, fee for service from MSD and GSK, outside the submitted work; In addition, NMvS has a patent WO 2013/020090 A3 with royalties paid to University of California San Diego (inventors: Nina van Sorge/Victor Nizet). All other authors did not declare any conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Files in this item

This item appears in the following Collection(s)